FDA weighs stricter SSRI warnings for pregnancy risks amid expert divide

A push for stricter warnings on antidepressants during pregnancy has gained momentum within the US Food and Drug Administration (FDA). Dr. Tracy Beth Hoeg, the agency's leading drug regulator, is accelerating a review of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed antidepressants for healthy pregnancy. The move follows years of debate over their safety, particularly for pregnant women and children.

Dr. Adam Urato, a vocal critic of SSRI use in pregnancy, has urged the FDA to add a boxed warning—the agency's strongest alert—about potential risks. He claims the drugs may cause complications, though his concerns remain contested by many researchers. Dr. Hoeg, who shares his caution, has fast-tracked the petition and aims to hire Urato as a full-time FDA advisor.

Over the past decade, public perception of SSRIs in pregnancy has shifted. Media reports and lawsuits have highlighted cases of neonatal withdrawal and congenital defects. Yet scientific reviews, including FDA updates and studies in journals like JAMA, suggest the benefits for severe depression often outweigh small risks, such as a slight rise in autism or heart defects.

Critics warn that a new warning could backfire. Outside experts fear pregnant women may stop taking medication abruptly, risking severe consequences from untreated pregnancy symptoms. The FDA has previously updated SSRI labels, including a black box warning in 2004 about suicidal behaviour in children. Now, the focus has turned to pregnancy risks, with Dr. Hoeg making the labelling change a top priority.

The proposed warning would mark another major shift in how SSRIs are regulated. If approved, it could alter treatment decisions for millions of pregnant women. The FDA's next steps will determine whether the agency adopts Urato's recommendations or maintains its current stance on balancing risks and benefits.